Geneos Wealth Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Geneos Wealth Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-100	Closed	-$1K	–	2567
2019 Q2	$1K	Buy	+100	New	+$1.15K	﹤0.01%	2465
2018 Q1	–	Sell	-500	Closed	-$6K	–	2251
2017 Q4	$6K	Hold	500	–	–	﹤0.01%	1793
2017 Q3	$4K	Hold	500	–	–	﹤0.01%	1857
2017 Q2	$8K	Sell	500 -500	-50%	-$9.94K	﹤0.01%	1618
2017 Q1	$20K	Hold	1,000	–	–	﹤0.01%	1248
2016 Q4	$15K	Buy	+1,000	New	+$13.5K	﹤0.01%	1315

Other funds holding ZYNE

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

ZCA

Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Geneos Wealth Management's ZYNE Position: Q3 2019 in Review

Geneos Wealth Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2019, closing a stake of 100 shares — an estimated $1K sold.

Geneos Wealth Management first reported a position in ZYNE in Q4 2016 and held it in 6 quarters. The position peaked at $20K in Q1 2017. 84 funds tracked by Wall St. Rank hold ZYNE as of Q3 2019.

Geneos Wealth Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2019 after selling out during the quarter.
Geneos Wealth Management sold 100 Zynerba Pharmaceuticals, Inc shares in Q3 2019, an estimated $1K.
Geneos Wealth Management first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2016 and held it in 6 quarters.
Geneos Wealth Management's Zynerba Pharmaceuticals, Inc position peaked at $20K in Q1 2017.
84 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2019.

Based on Geneos Wealth Management's 13F filing for Q3 2019, filed 7 Sep 2021.